Decubitus ulcer

Summary

Decubitus ulcer (MONDO:0004646) is a disease and 282 clinical trials. Top therapeutic interventions include collagenase clostridium histolyticum, fibrinogen i 125, and nitric oxide. A subtype of chronic ulcer of skin — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 282

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	decubitus ulcer
Mondo ID	MONDO:0004646
MeSH	D003668
DOID	DOID:8717
ICD-10-CM	L89
SNOMED CT	399912005
UMLS	C4554531
MedGen	1789997
Is cancer (heuristic)	no

Also known as: decubitus ulcer · decubitus ulcer, elbow · decubitus ulcer, lower back · decubitus ulcer, other site · decubitus ulcer, upper back · pressure sores · pressure ulcer

Disease family

This is a subtype of chronic ulcer of skin. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › chronic ulcer of skin › decubitus ulcer

Related subtypes (1): ulcer of lower limbs

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Glycerin	Approved (phase 4)
Collagenase Clostridium Histolyticum	Phase 3 (in late-stage trials)
Oxandrolone	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Thymosin.

Clinical trials & evidence

Clinical trials

Clinical trials: 282.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	234
PHASE4	15
PHASE3	10
PHASE2	9
PHASE1/PHASE2	6
PHASE1	4
EARLY_PHASE1	3
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06999590	PHASE4	RECRUITING	Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers
NCT07126886	PHASE4	RECRUITING	A Multicenter, Prospective, Clinical Trial Evaluating a Single Layer Amniotic Membrane and Standard of Care Versus Matched Controls in the Management of Nonhealing Pressure Ulcers
NCT07240649	PHASE4	NOT_YET_RECRUITING	Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications
NCT00521027	PHASE4	COMPLETED	Study Comparing VERSAJET With Conventional Surgical Procedures in the Removal of Unhealthy Tissue From Lower Limb Ulcers
NCT00691821	PHASE4	TERMINATED	Negative Pressure Wound Therapy for the Treatment of Chronic Pressure Wounds
NCT01438541	PHASE4	COMPLETED	A Multi-centre Evaluation of the Performance of Window Dressings on Subjects With High Risk Pressure Ulceration
NCT01595347	PHASE4	UNKNOWN	Olive Oil’s Cream Effectiveness in Prevention of Pressure Ulcers in Immobilized Patients in Primary Care
NCT01734109	PHASE4	UNKNOWN	Efficacy of Quantum NPWT With Simultaneous Irrigation on Reduction of Wound Volume in Stage III/IV Pressure Ulcers.
NCT02001558	PHASE4	COMPLETED	Pressure Ulcer Healing With Microcyn
NCT02224638	PHASE4	COMPLETED	Wound Management for Sacral Pressure Ulcers With Necrotic Tissue
NCT02587130	PHASE4	TERMINATED	Ketamine and Refractory Painful Care in a Palliative Unit
NCT02689310	PHASE4	WITHDRAWN	Leptospermum Scoparium Honey and Wound Care for Pressure Ulcers
NCT02716519	PHASE4	WITHDRAWN	Use of Santyl Within an Accountable Care Organization
NCT02718625	PHASE4	TERMINATED	Study of SANTYL® vs Hydrogel (SoloSite®) for Pressure Ulcers
NCT03823963	PHASE4	UNKNOWN	Study on Pressure Ulcers Prevention With Mepilex® Border Sacrum Dressing in Scheduled Cardiovascular Surgery
NCT07223892	PHASE3	NOT_YET_RECRUITING	Efficacy of Carbonlife Amniotic Tissue Product in the Treatment of Chronic Wounds
NCT00101361	PHASE3	TERMINATED	Oxandrolone to Heal Pressure Ulcers
NCT00665535	PHASE3	COMPLETED	Pressure Ulcer Prevention: Turning for Ulcer Reduction
NCT00796042	PHASE3	COMPLETED	Interdisciplinary Pressure Management & Mobility Program as an Alternative to Usual Care: A Pilot Study
NCT00847665	PHASE3	COMPLETED	Pressure Ulcer Prevention in Ventilated Patients Using Two Repositioning Regimens
NCT01008254	PHASE2/PHASE3	COMPLETED	Interdisciplinary Mobility Approach To Reduction Of Facility-Acquired Pressure Ulcers
NCT01211236	PHASE3	COMPLETED	Maggot Therapy for Wound Debridement
NCT01232764	PHASE3	COMPLETED	Pressure Ulcer Multi-disciplinary Teams Via Telemedicine (PUMTT): A Trial in Long Term Care
NCT01333670	PHASE3	COMPLETED	Efficacy of Prontosan Solution on Chronic Ulcers
NCT02004626	PHASE3	WITHDRAWN	Evaluate the Noninferiority of Medicines Treating Uninfected Pressure Ulcers.
NCT02565745	PHASE3	TERMINATED	Skin Dressings Versus Lubrication to Prevent Pressure Ulcers: A Randomized Trial
NCT02577120	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Wound Healing Endpoint and Recurrence
NCT05199077	PHASE2	NOT_YET_RECRUITING	A Study of GM-XANTHO in Pressure Ulcer Patients
NCT00007254	PHASE1/PHASE2	COMPLETED	Morphine Gel for Bedsores
NCT00382174	PHASE2	COMPLETED	Study of Thymosin Beta 4 in Patients With Pressure Ulcers
NCT00771368	PHASE1/PHASE2	TERMINATED	Reduction of Bacteria in MRSA Positive Ulcers
NCT00933348	PHASE2	SUSPENDED	Safety and Efficacy of the Fruit-based Product OPAL A for the Treatment of Chronic Venous and Pressure Ulcers
NCT01273428	PHASE2	WITHDRAWN	HP011-101, HP828-101, and Standard Care for Pressure Ulcers
NCT01351493	PHASE1/PHASE2	UNKNOWN	Study on the Safety and Efficacy of Nitric Oxide Gel in Subjects With Pressure Sore
NCT01433159	PHASE2	TERMINATED	Comparison of HP011-101 to Standard Care for Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury
NCT01877681	PHASE2	COMPLETED	Reference Nurse Program for Pressure Ulcers in Primary Care
NCT01966380	PHASE2	TERMINATED	Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia
NCT02092870	PHASE2	COMPLETED	Adipose Derived Regenerative Cellular Therapy of Chronic Wounds
NCT02418676	PHASE1/PHASE2	COMPLETED	Insulin Complexation With Hydroxypropyl-beta-cyclodextrin: Use of the Complex in Gel for Healing of Pressure Ulcers
NCT02585765	PHASE2	WITHDRAWN	Skin Blood Flow Response to Insulin Iontophoresis in Pressure Ulcers of SCI

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	4	4
FIBRINOGEN I 125	4	2
NITRIC OXIDE	4	2
PHENYTOIN	4	2
KETAMINE	4	1
OXANDROLONE	4	1
OXYGEN	4	1
SODIUM CHLORIDE	4	1
.BETA.-HYDROXYISOVALERIC ACID	3	1
ABAMECTIN	3	1
ALOE	3	1
DOCONEXENT	3	1
HONEY	3	1
ICOSAPENT	3	1
SESAME OIL	3	1
LUFENURON	2	1
CHEMBL4439413	0	1